AllianceRx Walgreens Prime studies the use of cyclin-dependent kinase 4/6 inhibitors in breast cancer patients
ORLANDO, Fla. —A recent study of metastatic breast cancer (MBC) patients, prescribed a class of drugs that interrupt malignant cell growth, revealed high rates of adherence, low side effects and low rates of patients stopping their medication. The class of drugs is known as cyclin-dependent kinase (CDK) 4/6 inhibitors. The retrospective study was conducted by AllianceRx
